Tanaka Yasuo, Tateishi Ryosuke, Koike Kazuhiko
Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.
Clin J Gastroenterol. 2019 Dec;12(6):588-591. doi: 10.1007/s12328-019-00997-5. Epub 2019 May 27.
Glecaprevir (GLE)/pibrentasvir (PIB) is a direct-acting antiviral regimen approved for patients infected with hepatitis C virus. No data are available on the safety and efficacy of this regimen when crushed and administered through a percutaneous endoscopic gastrostomy (PEG) tube. Here, we report a patient who successfully achieved a sustained viral response after treatment with GLE/PIB administered via a PEG tube. A 41-year-old female with chronic hepatitis C viral infection was referred to our department for treatment. She had a history of spina bifida and hydrocephalus, and she received a PEG tube for nutrition and medication due to an aftereffect of hydrocephalus. She received crushed GLE/PIB treatment through a PEG tube for 8 weeks and achieved a sustained viral response 12, without any treatment-related severe adverse events. This is the first documented case treated with GLE/PIB administered through a PEG tube. Based on this case report and a review of the literature, we discuss the safety and efficacy of direct-acting antiviral treatment via a PEG tube.
格卡瑞韦（GLE）/哌柏西利（PIB）是一种被批准用于丙型肝炎病毒感染患者的直接抗病毒治疗方案。关于该方案碾碎后通过经皮内镜下胃造口术（PEG）管给药的安全性和有效性尚无数据。在此，我们报告一名患者，其通过PEG管接受GLE/PIB治疗后成功实现了持续病毒学应答。一名41岁慢性丙型肝炎病毒感染女性被转诊至我科接受治疗。她有脊柱裂和脑积水病史，因脑积水后遗症接受了PEG管用于营养和给药。她通过PEG管接受碾碎的GLE/PIB治疗8周，在治疗结束后12周实现了持续病毒学应答，且未发生任何与治疗相关的严重不良事件。这是首例有记录的通过PEG管接受GLE/PIB治疗的病例。基于本病例报告及文献复习，我们讨论了通过PEG管进行直接抗病毒治疗的安全性和有效性。
